Coronavirus Notebook: China Generic Antiviral Filed For Emergency Approval
Confirmed Infections Surpass 20,000
Executive Summary
China is tightening oversight over suspected coronavirus cases, allowing hospitals to quarantine patients upon their first visit as confirmed infections surpass 20,000. Domestic firm Ascletis has meanwhile filed for the emergency approval of its generic version of AbbVie's Norvir (ritonavir) and a novel combo therapy.
You may also be interested in...
Coronavirus Notebook: Regeneron, HHS To Develop Antibody
Wuhan Institute of Pathology files patent over new use of Gilead's remdesivir and Regeneron expands collaboration with HHS to include 2019-nCoV.
GSK Joins Race To Tackle Coronavirus
The pharma major is providing its adjuvant system, designed to enhance the body’s immune response, to help the Coalition for Epidemic Preparedness Innovations' efforts to accelerate the creation of a vaccine for the coronavirus strain that broke out in China and has spread to 24 countries.
Gilead Joins Coronavirus Fray With Repurposed Antiviral
US antiviral specialist Gilead is working to provide its experimental drug remdesivir to treat the China coronavirus, while other potential treatments and alliances continue to emerge, including between Wuhan-based BravoVax and US venture GeoVax.